Maharashtra FDA cancels Cipla Pune licence from 27 August, UAE pharmacies should check recalls

Maharashtra Food and Drug Administration (FDA) cancelled the drug sale licences of Cipla Pharma & Life Sciences Ltd's carry-and-forwarding unit at Wadki, Pune, with the cancellation taking effect on 27 August 2026, after inspections tied to Reactin Plus tablets.

The highest-stakes readers in the UAE are pharmacy COOs, medical directors and insurer pharmacy-benefit teams. The Indian action does not mean a UAE recall has been issued. It does mean Dubai clinics, hospital pharmacies and community pharmacies should check whether any affected stock, substitute product or supplier documentation touches their own procurement chain before patients ask for answers at the counter.

What Maharashtra FDA found

Lokmat Times reported on 28 August 2026 that Maharashtra FDA cancelled the drug sale licences after serious irregularities in packaging, storage and distribution. The regulator's inspection in June 2026 focused on Reactin Plus, a Schedule H prescription medicine in India.

Indian media reports said the packaging carried unauthorised promotional wording, including the terms "analgesic and antipyretic". Maharashtra FDA also said it seized Reactin Plus stock worth more than Rs 11 lakh, ordered a market recall and later found incomplete compliance with recall directions.

"No negligence will be tolerated when it comes to the safety of medicines and public health."
— Tukaram Mundhe, commissioner, Maharashtra FDA

The follow-up inspection covered the Pune unit's drug sale and distribution system. Reported findings included discrepancies between physical stock and computerised inventory, gaps in purchase and sale records, medicines stored directly on the floor, inadequate pallet and rack arrangements, and weak procedures for expired medicines.

Why Dubai pharmacies should care first

For UAE operators, the immediate question is traceability. Dubai's private healthcare sector receives drug safety and recall notices through the Dubai Health Authority (DHA), often after circulars from the Ministry of Health and Prevention (MOHAP). A DHA circular dated 29 October 2025, for example, notified Dubai private health facilities about a voluntary recall of one batch of Dutasvitae and directed adherence to MOHAP's notice.

No DHA, Department of Health Abu Dhabi (DOH Abu Dhabi) or MOHAP notice reviewed for this article announced a UAE recall of Reactin Plus linked to the Maharashtra action. Operators should therefore separate three tasks: confirm whether the product is registered in the UAE, confirm whether any equivalent or parallel-sourced stock is on site, and preserve evidence that the check was completed.

• Dubai facilities: check DHA Sheryan circulars and internal pharmacy inventory on 29 August 2026, then document batch, expiry and supplier names.
• Abu Dhabi and Al Ain facilities: monitor DOH Abu Dhabi circulars, which listed USO/161/2026 for a separate medical product recall on 25 August 2026.
• Northern Emirates providers: check MOHAP circulars and licensed supplier communications before dispensing substitutes.
• Insurers including Daman, Thiqa and Sukoon: review formulary substitutions only against registered alternatives and agreed pharmacy-benefit rules.

Operational checks for clinics, insurers and patients

The P&L exposure is usually small at item level and larger in workflow time. A single low-price medicine may cost only a few dirhams per pack, but a recall check can consume pharmacist time, insurer approval time and replacement-dispensing work across multiple branches. UAE buyers should use their ERP, wholesaler invoices and insurer price files for the actual AED cost because public retail prices vary by product registration, pack size and payer contract.

Medical directors should watch the clinical-risk angle. The issue reported by Maharashtra FDA concerned prescription-medicine promotion, recall execution and storage controls. In a UAE clinic, that translates into four audit questions: was the medicine dispensed under a valid prescription, was patient counselling recorded where required, did the pharmacy check regulator alerts, and can the pharmacy trace the unit back to an authorised supplier?

Patients are affected through continuity of therapy. If a pharmacist withholds stock pending verification, the replacement decision should go through the prescribing clinician or payer rules, especially where insurance prior approval applies. Insurers should avoid blanket denials where a regulator-driven substitution is needed, because the patient may otherwise pay cash or interrupt therapy.

The next signal to watch is whether MOHAP, DHA or DOH Abu Dhabi issues a UAE-specific circular naming Reactin Plus, Cipla Pharma & Life Sciences, a batch number or an authorised local agent. Until then, UAE operators should treat this as a supplier-governance alert rather than a local recall. For licensed pharmacy options in Dubai, Abu Dhabi and the northern emirates, readers can check the UAE Open Healthcare Directory for licensed pharmacy providers.